Log in

NASDAQ:LOGC - LogicBio Therapeutics Stock Price, Forecast & News

$8.01
+0.17 (+2.17 %)
(As of 02/16/2020 04:00 PM ET)
Add
Today's Range
$7.72
Now: $8.01
$8.17
50-Day Range
$6.87
MA: $8.36
$11.00
52-Week Range
$6.34
Now: $8.01
$20.07
Volume52,529 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. Its lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. The company has a partnership with Children's Medical Research Institute to develop new viral vectors. LogicBio Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:LOGC
CUSIPN/A
CIKN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees23
Next Earnings Date4/6/2020 (Estimated)
OptionableNot Optionable

Receive LOGC News and Ratings via Email

Sign-up to receive the latest news and ratings for LOGC and its competitors with MarketBeat's FREE daily newsletter.


LogicBio Therapeutics (NASDAQ:LOGC) Frequently Asked Questions

What is LogicBio Therapeutics' stock symbol?

LogicBio Therapeutics trades on the NASDAQ under the ticker symbol "LOGC."

How were LogicBio Therapeutics' earnings last quarter?

LogicBio Therapeutics Inc (NASDAQ:LOGC) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.48) EPS for the quarter, missing the Zacks' consensus estimate of ($0.46) by $0.02. View LogicBio Therapeutics' Earnings History.

When is LogicBio Therapeutics' next earnings date?

LogicBio Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for LogicBio Therapeutics.

What price target have analysts set for LOGC?

3 brokers have issued 12 month price objectives for LogicBio Therapeutics' shares. Their forecasts range from $20.00 to $26.00. On average, they expect LogicBio Therapeutics' share price to reach $23.00 in the next year. This suggests a possible upside of 187.1% from the stock's current price. View Analyst Price Targets for LogicBio Therapeutics.

What is the consensus analysts' recommendation for LogicBio Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LogicBio Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for LogicBio Therapeutics.

What are Wall Street analysts saying about LogicBio Therapeutics stock?

Here are some recent quotes from research analysts about LogicBio Therapeutics stock:
  • 1. According to Zacks Investment Research, "LogicBio Therapeutics Inc. is a genome editing company. It focuses on developing medicines to treat rare diseases in patients with significant unmet medical needs. The company's technology platform consists of GeneRide(TM). LogicBio Therapeutics Inc. is based in Cambridge, Massachusetts. " (11/14/2019)
  • 2. Chardan Capital analysts commented, "We see limited read-across on nuclease-free editing controversy On 21 July, researchers from the California posted a manuscript to the bioRxiv preprint server outlining outlining unsuccessful efforts to reproduce efficient nuclease-free genome editing with clade F AAV vectors, based on a 2018 publication from Homology Medicines (unrated), which reported >50% editing with similar AAV vectors isolated from hematopoietic stem cells (AAVHSCs). Increasing attention drawn to the preprint to us may have sent Homology’s share price down >20% by the market close on July 25th. Below, we highlight some considerations for interpreting the data and the extent of potential read-across for other companies in the space." (7/29/2019)

Has LogicBio Therapeutics been receiving favorable news coverage?

News stories about LOGC stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. LogicBio Therapeutics earned a news sentiment score of 2.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for LogicBio Therapeutics.

What other stocks do shareholders of LogicBio Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other LogicBio Therapeutics investors own include Acceleron Pharma (XLRN), Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), Pfizer (PFE), Crispr Therapeutics (CRSP), NVIDIA (NVDA), AbbVie (ABBV) and Bristol-Myers Squibb (BMY).

Who are LogicBio Therapeutics' key executives?

LogicBio Therapeutics' management team includes the folowing people:
  • Mr. Frederic Chereau, Pres, CEO & Director (Age 52)
  • Mr. Matthias B. Jaffé, Chief Financial Officer (Age 50)
  • Mr. Tom Wilton, Chief Bus. Officer (Age 45)
  • Dr. Leszek Lisowski Ph.D., Co-Founder
  • Dr. Adi Barzel, Co-Founder

When did LogicBio Therapeutics IPO?

(LOGC) raised $77 million in an IPO on Friday, October 19th 2018. The company issued 5,800,000 shares at a price of $12.50-$14.00 per share. Jefferies, Barclays and William Blair acted as the underwriters for the IPO and Chardan was co-manager.

Who are LogicBio Therapeutics' major shareholders?

LogicBio Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Samlyn Capital LLC (3.23%), Board of Trustees of The Leland Stanford Junior University (3.21%), State Street Corp (0.56%), Fiduciary Trust Co. (0.14%), Goldman Sachs Group Inc. (0.11%) and Oxford Asset Management LLP (0.08%). View Institutional Ownership Trends for LogicBio Therapeutics.

Which major investors are selling LogicBio Therapeutics stock?

LOGC stock was sold by a variety of institutional investors in the last quarter, including Board of Trustees of The Leland Stanford Junior University. View Insider Buying and Selling for LogicBio Therapeutics.

Which major investors are buying LogicBio Therapeutics stock?

LOGC stock was acquired by a variety of institutional investors in the last quarter, including Samlyn Capital LLC, Fiduciary Trust Co., Oxford Asset Management LLP, State Street Corp, Barclays PLC, UBS Group AG and Goldman Sachs Group Inc.. View Insider Buying and Selling for LogicBio Therapeutics.

How do I buy shares of LogicBio Therapeutics?

Shares of LOGC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is LogicBio Therapeutics' stock price today?

One share of LOGC stock can currently be purchased for approximately $8.01.


MarketBeat Community Rating for LogicBio Therapeutics (NASDAQ LOGC)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  62 (Vote Outperform)
Underperform Votes:  76 (Vote Underperform)
Total Votes:  138
MarketBeat's community ratings are surveys of what our community members think about LogicBio Therapeutics and other stocks. Vote "Outperform" if you believe LOGC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LOGC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel